搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
BioWorld
4 小时
Neo Medical gets MDR approval for spine care platform
Neo Medical SA received certification under the EU Medical Device Regulation for its entire portfolio of spine surgical ...
12 小时
Drug acoramidis to treat rare heart disease approved by FDA
The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...
BioWorld
1 天
Tolerogenic assets at heart of Cour-Genentech $940M autoimmune deal
During a busy day of dealmaking, Cour Pharmaceutical Development Co. Inc. entered a pact with Roche Holding AG’s Genentech ...
Managed Healthcare Executive
1 天
Johnson and Johnson Submits FDA Request for Pediatric Tremfya Approval
If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...
2 天
11/23
11/23,FDA 批准 BridgeBio Pharma $BridgeBio Pharma(BBIO)$ 的 Attruby (acoramidis) 用于降低转甲状腺素蛋白淀粉样心肌病 (ATTR-CM) 患者的心血管死亡和心血管相关住院率,与辉瑞的 tafamidis 展开直接竞争,后者具有相同的作用机制,但批准的适应症更有限。 Attruby 是一种口服 TTR 稳定剂,FDA的批准称该 ...
The Pharma Letter
2 天
The week in pharma: action, reaction and insight – week to November 29
Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...
4 天
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
Opinion
6 天
Opinion
A Short Lesson in Drug Competition
See the new treatment that will break a Pfizer monopoly on a drug for heart disease.
BioPharma Dive
6 天
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC ...
6 天
Deutsche Bank Aktiengesellschaft Forecasts Strong Price Appreciation for Bath & Body Works ...
Bath & Body Works (NYSE:BBWI – Free Report) had its target price increased by Deutsche Bank Aktiengesellschaft from $51.00 to ...
ETF Daily News
7 天
BridgeBio Pharma (NASDAQ:BBIO) Receives FDA Approval for ATTR-CM Treatment ‘Attruby ...
The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈